Mirada Solutions and Hitachi Medical Systems America Announce the Release of a New Edition of Fusion7D for the AVIA Workstation

Share Name	Share Symbol	Market	Type
Cti Molecular Imaging - Common Stock (MM)	NASDAQ:CTMI	NASDAQ	Common Stock

Cti Molecular Imaging (NASDAQ:CTMI)
Historical Stock Chart

From Jun 2019 to Jun 2024

Click Here for more Cti Molecular Imaging Charts.

Mirada Solutions and Hitachi Medical Systems America Announce the Release of a New Edition of Fusion7D for the AVIA Workstation OXFORD, England, June 24 /PRNewswire-FirstCall/ -- Mirada Solutions Ltd. (a subsidiary of CTI Molecular Imaging, Inc.), leaders in software for molecular imaging, and Hitachi Medical Systems America (HMSA) announced today the release of the latest edition of Fusion7D(TM) for the AVIA(TM) workstation and plans for extending further PET and PET/CT analysis tools to Hitachi customers. Fusion7D is the leading image fusion and analysis package for PET and PET/CT. It is fully integrated onto the AVIA multi-modality workstation, bringing advanced PET analysis and image fusion software into the hands of PET practitioners. This latest release provides a range of new features and further streamlines the review and analysis workflow for PET and PET/CT. Future product extension plans revealed by the companies include offering Mirada's PET/CT viewer and RTist(TM) applications on AVIA(1). RTist provides a complete set of contouring and structure delineation tools for PET/CT and fusion imaging with support for DICOM RT structure sets. This enables fusion data to be contoured and sent (along with images) directly to treatment planning systems, further positioning PET/CT as an integrated oncology tool. Christian P. Behrenbruch Ph.D., President of Mirada Solutions, commented "Hitachi was our first Fusion7D OEM customer and we are pleased to be continuing the product line by adding new functions like support for radiation therapy. Our timing of this release of Fusion7D coincides with the announcement of Hitachi's new PET/CT scanner. We look forward to providing new and additional software tools for PET/CT review and therapy to work with this outstanding system." Bill Bishop, Vice President for Business Development at HMSA, stated "Hitachi continues to enjoy an excellent and highly productive relationship with the team at Mirada. The additional tools and product structuring helps to position our AVIA workstation as a winning platform for PET, PET/CT and multimodal review." About Mirada Solutions: Mirada Solutions Limited, a wholly owned subsidiary of CTI Molecular Imaging, is a leading developer of software and analytical tools for medical imaging workstations, OEM imaging platforms and pharmaceutical applications. Mirada's unique products aid in better detection, diagnosis and management of disease through the application of powerful algorithms, quantification tools and image analysis. Additional information is available at http://www.mirada-solutions.com/ . About CTI Molecular Imaging: CTI Molecular Imaging, Inc. is a leading supplier of products and services for positron emission tomography (PET), a diagnostic imaging technology used in the detection and treatment of cancer, cardiac disease and neurological disorders. Additional information is available at: http://www.ctimi.com/ . Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as "believe," "assume," "expect," "anticipate," "intend," "estimate" or similar expressions, and any other statements that necessarily depend on future events. Forward-looking statements involve a number of risks and uncertainties and there can be no assurance that any forward-looking statements will prove to be accurate. Various factors could cause actual results to differ materially from those anticipated in the forward-looking statements. CTI undertakes no obligation to update or revise any forward- looking statements. Further information regarding risks, uncertainties and other factors that could adversely affect CTI or cause actual results to differ materially from those anticipated in forward-looking statements are included in CTI's Annual Report on Form 10-K for the fiscal year ended September 30, 2003, Quarterly Report on Form 10-Q for the quarter ended March 31, 2004. Notes: (1) RTist integration planned for release in Q4, 2004. DATASOURCE: CTI Molecular Imaging, Inc., Mirada Solutions Ltd. CONTACT: Clare F. Jones of Mirada Solutions Ltd., +44-1865-265-500; or Michael A. Lawless of CTI Molecular Imaging, Inc., +1-865-218-2000 Web site: http://www.ctimi.com/ http://www.mirada-solutions.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

CTMI Cti Molecular Imaging - Common Stock (MM)